TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04251156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
Study: NCT03957590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administrated at dose of 200 mg intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match tislelizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Administered as 135 mg/m² IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered as 135 mg/m² IV injection
Study: NCT03570138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System
Description: Specific therapeutic education for diabetes self management

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual self monitoring Blood Glucose device
Description: Standard therapeutic education for diabetes self management
Study: NCT02970188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: consuming all daily calories within an 8 hour feeding window
Study: NCT02573662

Intervention type: BIOLOGICAL
Intervention: Blood and Urine sampling
Description: Blood and Urine Sampling
Study: NCT00469014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
Study: NCT02573662

Intervention type: BIOLOGICAL
Intervention: Blood and Urine sampling
Description: Blood and Urine Sampling

Intervention type: RADIATION
Intervention: DXA scan
Description: Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
Study: NCT00469014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin (ATG)
Description: Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
Study: NCT02573662

Intervention type: RADIATION
Intervention: DXA scan
Description: Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue

Intervention type: BIOLOGICAL
Intervention: OGTT
Description: Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation

Intervention type: BIOLOGICAL
Intervention: OGTT
Description: Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
Study: NCT05104996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
Study: NCT03577561

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proficiency Based Progression Training in Phlebotomy
Description: Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proficiency Based Progression Training in Phlebotomy
Description: Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
Study: NCT01129258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
Study: NCT00469014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
Study: NCT01129258

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
Study: NCT03616379

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducational Control
Description: The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
Study: NCT00736736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Hip Muscle Strengthening to Leg Press Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leg Press Exercise
Study: NCT01905267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rumination-Focused Cognitive Behavior Therapy
Description: This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
Study: NCT03616379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Regulation
Description: In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Labelling
Description: In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
Study: NCT04381559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: In sessions 1-2, the participant's sexual history and goals regarding social anxiety reduction and HIV risk reduction will be discussed, including reducing CAS, and considering use of PrEP to reduce HIV risk. In sessions 3-4, the role of social anxiety and substances in social avoidance and HIV risk will be discussed, and a fear hierarchy of the participant's social fears will be created. In sessions 5-7, cognitive restructuring and coping skills for anxiety reduction will be discussed. In sessions 8-9, participants will face their fears via exposures to feared situations using their new cognitive coping skills. In sessions 10-11, exposures are continued with a focus on (a) situations higher in the fear hierarchy and (b) the role of substance use as a barrier to personal goals. In session 12, relapse prevention and goals for progress regarding social anxiety, substance use, and HIV risk reduction beyond the end of therapy will be discussed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied Relaxation
Description: 12 sessions of AR will serve as our second, control arm. In AR, patients are trained in progressive muscle relaxation, and then taught to practice using relaxation when facing feared situations, as a new coping response.86 AR involves noticing early signs of anxiety, learning relaxation skills, and applying relaxation at the first sign of anxiety.87 This therapy is chosen because it does not involve the cognitive and exposure focused techniques that are used in the experimental condition.88 Reviews of psychological treatments show that AR does not statistically differ from cognitive restructuring with exposure in its effects on social anxiety.87 However, AR is an appropriate control arm for the present study because it is credible and can be time-matched to CBT, but has no theoretical or empirical support for substance use management or HIV risk behaviour reduction, the latter of which is the primary outcome of the present study.
Study: NCT00730600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thai Traditional massage
Description: Thai traditional massage for 2 hours by a single masseuse.
Study: NCT02429167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial nerve non-invasive neuromodulation via PoNS device
Description: The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PoNS device
Description: The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
Study: NCT03109392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Lignocaine
Description: 2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine spray
Description: 10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined spray and nebulization
Description: Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
Study: NCT05692557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The Oculus Rift's (Lenovo, Beijing, China) Fujii - Mystical Journey was the game played by the VRD group on a tablet. The game is a peaceful, ethereal voyage that passes through several surreal, natural locations.~The game combines elements of adventure, agriculture and revitalizing music. It alternates between outdoor exploration and inventive gardening. Players explore three different magical biomes. The life force in each biome is restored by interacting with the plants and animals there.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: The patients of the control group performed Progressive muscle relaxation technique, a relaxation technique used to control pain. It is believed that anxiety-inducing thoughts result in muscle tension and hence muscle relaxation can reduce anxiety. The relaxation technique consisted of tensing and relaxing different muscles, starting from the toes and finally involving muscles of the head and neck. It was recommended that this be done in a peaceful, distraction-free environment. The muscle groups were tensed for a period of 5 seconds and then relaxed for 30 seconds.
Study: NCT03124758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))
Description: Measurement of Noninvasive Hemoglobin (SpHb)
Study: NCT00866476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 1208S, a Shigella flexneri 2a live, oral vaccine
Description: CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
Study: NCT04671147

Intervention type: PROCEDURE
Intervention: Preoperative traction
Description: Compare two methods of preoperative traction (Cotrel traction exercises and skull tongs femoral traction)
Study: NCT02739880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)
Description: Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total.
Study: NCT02666482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Smoking SF Web App - baseline
Description: Smoking cessation web app in Spanish and English. Accessible online at no charge.
Study: NCT02858037

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring
Description: Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
Study: NCT02293486

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
Study: NCT03784274

Intervention type: BEHAVIORAL
Intervention: Stakeholder analysis
Description: • INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~* Respondents who consent to participate in the study.~* Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA).
Study: NCT01696305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalobarrier

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guardix-SG
Study: NCT02760433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Study: NCT02911636

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic SABR with intra-prostatic SABR
Description: described elsewhere
Study: NCT01859260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP/autopap
Study: NCT04443049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg
Study: NCT00469014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
Study: NCT04443049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: mebendazole will be given at dose of 100 mg orally twice a day (BD) daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (Tab Mecovit) orally twice a day (BD) daily
Study: NCT02498938

Intervention type: GENETIC
Intervention: SERPINA1 gene
Description: 2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
Study: NCT05025163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.23% fluoride foam application
Description: topical application of fluoride foam every 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.26% fluoride varnish application
Description: topical application of fluoride varnish every 6 months
Study: NCT02840669

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac magnetic resonance imaging (CMR)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac magnetic resonance imaging (CMR)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise-stress test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise-stress test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiography (ECHO)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiography (ECHO)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac-related blood studies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac-related blood studies
Study: NCT01037231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes
Description: NLT (not less than) 10\^7 CFU oxalobacter formigenes twice daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02075333

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ingestion of solution
Description: Participants will ingest the solution

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of solution
Description: Participants will ingest the solution

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rinising of solution
Description: Participants rinse the solution in the oral cavity
Study: NCT00469014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
Study: NCT05639803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGIFNα1b
Description: 100μg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGIFNα1b
Description: 100μg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGIFNα1b
Description: 100μg/vial
Study: NCT00469014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
Study: NCT00455858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
Study: NCT02420964

Intervention type: OTHER
Group type: OTHER
Intervention: video instruction
Description: Patient Directed Video Instruction

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse instruction
Description: Nurse directed instruction